Pharmamarketeer

Valneva COVID-19 vaccine shown to be more effective than AstraZeneca candidate

French biotech company, Valneva, has announced positive results from the Phase III trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

The Phase III, Cov-Compare trial recruited a total of 4,012 participants, aged 18 years and older, across 26 trial sites in the UK. The trial successfully met both co-primary endpoints: VLA2001 had superior antibody titer levels compared to the active comparator vaccine, AstraZeneca’s AZD1222, and it had a neutralising antibody seroconversion rate above 95%.

 

Medhc-fases-banner
Advertentie(s)